(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)carbamate | 666830-45-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)carbamate
• 英文别名: (7-Hydroxynaphthalen-1-yl)carbamic acid
• CAS: 666830-45-1
• 化学式: C₁₁H₉NO₃
• 分子量: 203.197
• InChiKey: WLWBQBAYCFGRFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)carbamate 、 1-(邻氯苯基)哌嗪盐酸盐 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 4-(2-chlorophenyl)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)piperazine-1-carboxamide
  参考文献：
  名称：

  [EN] TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES
  [FR] TETRAHYDRO-NAPHTALENE ET DERIVES D'UREE

  摘要：

  这项发明涉及一种羟基四氢萘或脲衍生物公式(I)及其盐，它们作为药物制剂的活性成分，其中A代表公式(II)或(III)，其中#代表分子的连接位置，Q1a、Q2a、Q3a和Q4a被定义，E代表公式(IV)或(V)，其中#代表分子的连接位置，Q1b、Q2b、Q3b、Q4b、Q5b、R1b、na、ma、Xa和Ra被定义。

  公开号：

  WO2005040119A1

文献信息

• Amine derivative compounds
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030078426A1

  公开（公告）日：2003-04-24

  An amine compound of the formula (I): 1 wherein R 1 represents an optionally substituted carbamoyl group, etc., R 2 represents a hydrogen atom, etc., R 3 represents a C 1 -C 10 alkyl group etc., W 1 , W 2 and W 3 are the same or different and each represent a single bond or a C 1 -C 8 alkylene group, X, Y and Q represent a sulfur atom, etc., Z represents a ═CH— group, etc., Ar represents a benzene ring, etc. and L represents a hydrogen atom, etc., or a pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.

  化合物的结构式（I）如下：其中R1代表可选择取代的氨基甲酰基团，R2代表氢原子等，R3代表C1-C10烷基等，W1、W2和W3相同或不同，每个代表单键或C1-C8烷基链，X、Y和Q代表硫原子等，Z代表═CH—基团等，Ar代表苯环等，L代表氢原子等，或其药理学上可接受的盐。这些化合物在治疗和/或预防糖尿病、高脂血症、动脉硬化、癌症等疾病方面具有用处。
• [EN] TETRAHYDRO-NAPHTHALENE DERIVATIVES AS VANILLOID RECEPTOR ANTAGONISTS<br/>[FR] DERIVES TETRAHYDRO-NAPHTALENE SERVANT D'ANTAGONISTES DU RECEPTEUR VANILLOIDE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004052845A1

  公开（公告）日：2004-06-24

  This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

  该发明涉及四氢萘衍生物及其盐，作为药物制剂的活性成分。本发明的四氢萘衍生物作为VR1拮抗剂具有出色的活性，并且适用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、急迫性尿失禁、过度活动膀胱、慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、炎症性疾病、哮喘和慢性阻塞性肺疾病的治疗。
• New compounds with antiglutamatergic properties and uses thereof
  申请人：Faust Pharmaceuticals

  公开号：EP1961738A1

  公开（公告）日：2008-08-27

  The present invention provides new compounds displaying antiglutamatergic properties. It also provides the use of such compounds for the treatment and/or prophylaxis of conditions and diseases linked to abnormalities in glutamatergic transmission. It further provides a pharmaceutical composition for the treatment and/or prophylaxis of acute and chronic neurodegenerative conditions and disorders.

  本发明提供了显示抗谷氨酸作用的新化合物。它还提供了利用这些化合物治疗和/或预防与谷氨酸传递异常相关的疾病和疾病的用途。此外，还提供了用于治疗和/或预防急性和慢性神经退行性疾病和疾病的药物组合物。
• [EN] TETRAHYDRO-NAPHTHALENE DERIVATIVES<br/>[FR] DERIVES DE TETRAHYDRO-NAPHTHALENE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004052846A1

  公开（公告）日：2004-06-24

  This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, post-operative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

  这项发明涉及四氢萘衍生物及其盐，可用作药物制剂的活性成分。本发明的四氢萘衍生物具有出色的VR1拮抗活性，适用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁、膀胱过度活跃、急迫性尿失禁、慢性疼痛、神经病痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、炎症性疾病、哮喘和慢性阻塞性肺疾病的治疗。
• Tetrahydro-naphthalene derivatives
  申请人：Tajimi Masaomi

  公开号：US20060128704A1

  公开（公告）日：2006-06-15

  This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I) in which R 1 represents hydrogen or C 1-6 alkyl, and X represents —N(H)Y 1 , —N(H)—C 1-6 alkylene Y 1 , biphenyl or C 1-6 alkyl substituted by biphenyl, and the group Y 1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

  本发明涉及四氢萘衍生物及其盐，其可作为药物制剂的活性成分。它们具有通式（I），其中R1代表氢或C1-6烷基，X代表-N（H）Y1，-N（H）-C1-6烷基Y1，联苯或被联苯取代的C1-6烷基，而Y1是一个可选的取代联苯。本发明的四氢萘衍生物作为VR1拮抗剂具有出色的活性，并可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗尿失禁，过度活动的膀胱，急迫性尿失禁，慢性疼痛，神经性疼痛，术后疼痛，类风湿性关节炎疼痛，神经痛，神经病，疼痛，神经损伤，缺血，神经退行性疾病，中风，炎症性疾病，哮喘和COPD的治疗。